Camizestrant Reduced the Risk of Disease Progression or Death by 56% in Patients With Advanced HR-Positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Phase III Trial
June 03, 2025
June 03, 2025
WILMINGTON, Delaware, June 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
First pivotal trial to demonstrate clinical value of monitoring circulating tumor DNA to detect and treat emerging resistance in 1st-line therapy ahead of disea . . .
* * *
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
First pivotal trial to demonstrate clinical value of monitoring circulating tumor DNA to detect and treat emerging resistance in 1st-line therapy ahead of disea . . .